As part of a series of strategic moves to build its laboratory information management system (LIMS) business in Europe and emerging markets in Latin America and Africa, STARLIMS Technologies, a subsidiary of US health care major Abbott (NYSE: ABT), has announced the acquisition of several longtime distribution partners.
These acquisitions include STARLIMS' French distributor Varilab; operations of two privately held Spanish businesses, now operating as STARLIMS Iberica; a privately-held Dutch company, now operating as STARLIMS Netherlands, with a branch office in Solna, Sweden; and the business of its Israeli distribution partner, STARLIMS Israel. In addition, the company established STARLIMS Germany GmbH, with offices in Witten, Germany, to provide direct support for its German and Swiss customers.
"The successful completion of these transactions represents Abbott's commitment to invest in and accelerate the growth of STARLIMS's core business," said Isaac Friedman, head of Abbott's STARLIMS business. "With these acquisitions, we now have more than 100 experienced LIMS engineers in the region allowing us to better serve our fast-growing European customer base and further strengthen our position as a leading provider of laboratory information management systems in Europe and other important markets," he noted.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze